Isolated Kratom Use Disorder Treated With Extended-Release Buprenorphine Taper.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38776432.
- Also identified by DOI 10.1097/ADM.0000000000001328.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case report highlights a 36-year-old male without history of psychiatric disease, chronic pain, or substance use disorder who developed severe substance use disorder per Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition criteria to kratom. He was successfully treated with sublingual buprenorphine after a 3-year period of intermittent withdrawal management and trials of oral and extended-release injectable naltrexone. After a period of abstinence from kratom, he was tapered from buprenorphine using 2 monthly injections of 100 mg extended-release buprenorphine. His case underscores some of the current uncertainties around kratom use disorder diagnosis and treatment.
Medical subject headings
- Buprenorphine
- Delayed-Action Preparations
- Mitragyna
- Narcotic Antagonists